scPharmaceuticals (SCPH) Competitors $4.07 -0.08 (-1.93%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SCPH vs. OPTN, CHMA, CMRX, FBIO, MBIO, MREO, EXAI, SLRN, TRDA, and VECTShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include OptiNose (OPTN), Chiasma (CHMA), Chimerix (CMRX), Fortress Biotech (FBIO), Mustang Bio (MBIO), Mereo BioPharma Group (MREO), Exscientia (EXAI), Acelyrin (SLRN), Entrada Therapeutics (TRDA), and VectivBio (VECT). These companies are all part of the "medical" sector. scPharmaceuticals vs. OptiNose Chiasma Chimerix Fortress Biotech Mustang Bio Mereo BioPharma Group Exscientia Acelyrin Entrada Therapeutics VectivBio scPharmaceuticals (NASDAQ:SCPH) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations. Does the MarketBeat Community believe in SCPH or OPTN? OptiNose received 87 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.39% of users gave scPharmaceuticals an outperform vote while only 63.31% of users gave OptiNose an outperform vote. CompanyUnderperformOutperformscPharmaceuticalsOutperform Votes15866.39% Underperform Votes8033.61% OptiNoseOutperform Votes24563.31% Underperform Votes14236.69% Which has more volatility and risk, SCPH or OPTN? scPharmaceuticals has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Does the media favor SCPH or OPTN? In the previous week, scPharmaceuticals had 1 more articles in the media than OptiNose. MarketBeat recorded 1 mentions for scPharmaceuticals and 0 mentions for OptiNose. OptiNose's average media sentiment score of 1.87 beat scPharmaceuticals' score of 0.53 indicating that OptiNose is being referred to more favorably in the news media. Company Overall Sentiment scPharmaceuticals Positive OptiNose Very Positive Do analysts prefer SCPH or OPTN? scPharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 342.26%. OptiNose has a consensus target price of $4.00, indicating a potential upside of 491.72%. Given OptiNose's higher probable upside, analysts clearly believe OptiNose is more favorable than scPharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00OptiNose 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SCPH or OPTN more profitable? OptiNose has a net margin of -54.50% compared to scPharmaceuticals' net margin of -252.18%. OptiNose's return on equity of 0.00% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-252.18% -201.84% -70.42% OptiNose -54.50%N/A -38.53% Do insiders & institutionals believe in SCPH or OPTN? 89.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 85.6% of OptiNose shares are held by institutional investors. 5.5% of scPharmaceuticals shares are held by insiders. Comparatively, 2.7% of OptiNose shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, SCPH or OPTN? OptiNose has higher revenue and earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than OptiNose, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$24.05M8.47-$54.81M-$1.56-2.61OptiNose$75.06M1.36-$35.48M-$0.36-1.88 SummaryOptiNose beats scPharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$203.62M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-2.6112.35128.4016.13Price / Sales8.47396.051,491.7792.21Price / CashN/A47.4339.5634.18Price / Book3.915.604.765.07Net Income-$54.81M$153.56M$118.92M$225.46M7 Day Performance-3.10%-1.46%-0.39%0.07%1 Month Performance-3.33%15.32%6.06%3.93%1 Year Performance-22.18%43.07%38.23%32.51% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals3.5044 of 5 stars$4.07-1.9%$18.00+342.3%-22.2%$207.62M$13.59M-2.6130OPTNOptiNose3.4218 of 5 stars$0.77-2.3%$4.00+418.5%-45.7%$116.31M$70.99M-2.14190Gap DownCHMAChiasmaN/A$3.76flatN/A+0.0%$217.68M$1.11M-2.3485Analyst ForecastCMRXChimerix4.3888 of 5 stars$0.87+0.3%$8.50+874.3%+3.1%$78.19M$144,000.00-0.9272Upcoming EarningsNews CoverageFBIOFortress Biotech2.8545 of 5 stars$1.85+6.9%$13.00+602.7%+13.1%$37.76M$82.62M-0.57186High Trading VolumeMBIOMustang Bio2.6093 of 5 stars$0.29-0.2%$2.00+589.9%-83.0%$10.79MN/A-0.11100Gap DownMREOMereo BioPharma Group1.7813 of 5 stars$4.26-2.1%$7.50+76.1%+114.0%$597.50M$1M0.0040Positive NewsEXAIExscientia1.4408 of 5 stars$4.92+2.5%$7.00+42.3%-7.5%$594.76M$21.02M-3.78280Positive NewsSLRNAcelyrin3.1337 of 5 stars$5.97flat$11.17+87.0%-38.4%$591.19MN/A-2.10135Upcoming EarningsTRDAEntrada Therapeutics2.4135 of 5 stars$16.99+0.9%$21.50+26.5%+13.5%$573.57M$239.40M5.74110Upcoming EarningsPositive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030 Related Companies and Tools Related Companies OptiNose Alternatives Chiasma Alternatives Chimerix Alternatives Fortress Biotech Alternatives Mustang Bio Alternatives Mereo BioPharma Group Alternatives Exscientia Alternatives Acelyrin Alternatives Entrada Therapeutics Alternatives VectivBio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
